This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Norihisa Shigemura Hikaru Matsuda Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shigemura, N. Articles by Matsuda, H. Search for Related Content PubMed PubMed Citation Articles by Shigemura, N. Articles by Matsuda, H. Related Collections Lung - cancer

Combined surgery of intrapleural perfusion hyperthermic chemotherapy and panpleuropneumonectomy for lung cancer with advanced pleural spread: a pilot study

^a Division of the General Thoracic Surgery, Takarazuka Municipal Hospital, Hyogo, Japan
^b Department of Surgery, Osaka University Graduate School of Medicine, E1, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

^* Corresponding author. Department of Surgery, Osaka University Graduate School of Medicine, E1, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Tel.: +81-6-6879-3152; fax: +81-6-6879-3163
n-shige{at}blue.ocn.ne.jp

For the treatment of lung cancer with advanced pleural spread, aggressive local treatment could offer a chance of cure. This study evaluates the early and midterm results of our Phase I trial for the new modality of two-stage approach combining thoracoscopic intrapleural perfusion hyperthermic chemotherapy (TIPHC) and panpleuropneumonectomy for the disease. Five patients were enrolled in this study. All had proven lung cancer with major malignant pleural effusion or numerous pleural dissemination. The combined regimen was planned first with TIPHC using high doses of cisplatin, followed by a second stage with panpleuropneumonectomy with full-thoracotomy approach as radical surgery. All patients successfully completed this treatment, and there were no serious complications. Panpleuropneumonectomy was performed 14±1.2 days after TIPHC, and the mean operation time was 280±35 min, the blood loss was 620±89 ml. One patient with pathological N2 developed liver metastases 8 months after surgery and died. The other four patients are living and have not experienced any recurrence to date. The mean survival time is 19 months, and the longest is 32 months. Our new treatment modality is feasible and seems to provide a possibility for safe and effective radical local tumor control for patients of lung cancer with advanced carcinomatous pleuritis.

Key Words: Hyperthermic chemotherapy; Lung cancer; Carcinomatous pleuritis; Malignant effusion; Panpleuropneumonectomy; Cisplatin